Drug Trial Radar · NCT04338061
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)
Last checked: Nov 20, 2026Latest source record: Mar 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,166
Actual
Start
Jul 2, 2020
Primary completion
Oct 2, 2023
Study completion Mar 19, 2024
Sponsor
- Lead sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyIndustry
- Sponsor type
- Industry
- Collaborators
- EMD Serono Research & Development Institute, Inc.
- First posted
- Apr 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.
Conditions
- Relapsing Multiple Sclerosis
Interventions
TeriflunomideDrug
Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period.
EvobrutinibDrug
Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)Time frame: Baseline up to 170 weeks
Locations
278 sites in 32 countries. Site status is shown where the registry gives one.
Research Site 752
Cullman, Alabama
Research Site 741
Scottsdale, Arizona
Research Site 704
Tucson, Arizona
Research Site 751
Hanford, California
Research Site 737
West Hollywood, California
Research Site 759
Colorado Springs, Colorado
Research Site 725
Fort Collins, Colorado
Research Site 746
Altamonte Springs, Florida
Research Site 718
Jacksonville, Florida
Research Site 702
Naples, Florida
Research Site 740
Orlando, Florida
Research Site 726
Port Charlotte, Florida
Research Site 719
Sarasota, Florida
Research Site 743
Tampa, Florida
Research Site 707
Tampa, Florida
Research Site 732
Vero Beach, Florida
Research Site 705
Weeki Wachee, Florida
Research Site 753
West Palm Beach, Florida
Research Site 742
Honolulu, Hawaii
Research Site 715
Evanston, Illinois
Research Site 714
Fort Wayne, Indiana
Research Site 744
Lafayette, Indiana
Research Site 717
Overland Park, Kansas
Research Site 735
Nicholasville, Kentucky
Research Site 706
Scarborough, Maine
Research Site 738
Detroit, Michigan
Research Site 723
St Louis, Missouri
Research Site 724
Amherst, New York
Research Site 736
Asheville, North Carolina
Research Site 712
Chapel Hill, North Carolina
Research Site 730
Raleigh, North Carolina
Research Site 728
Winston-Salem, North Carolina
Research Site 711
Canton, Ohio
Research Site 757
Columbus, Ohio
Research Site 734
Dayton, Ohio
Research Site 748
Philadelphia, Pennsylvania
Research Site 703
San Antonio, Texas
Research Site 721
Norfolk, Virginia
Research Site 143
Grodno, Belarus
Research Site 144
Homyel, Belarus
Showing 40 of 278 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.